A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
NCT ID: NCT03399643
Last Updated: 2019-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
22 participants
OBSERVATIONAL
2017-12-28
2019-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
NCT02589717
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
NCT02928406
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
NCT03029832
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
NCT04624399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab is administered via IV 1200 mg every 3 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Will be receiving atezolizumab for the treatment of inoperable locally-advanced or metastatic UC, per the decision of the treating physician
* Have adequate hematologic and end-organ functions
* Have had no prior palliative chemotherapy for inoperable locally-advanced or metastatic UC and are clinically ineligible ("unfit") for cisplatin-based chemotherapy
Exclusion Criteria
* Are pregnant or breastfeeding
* Are included in any other trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Praxis Dr.med. Wolfgang Hölzer
Berlin, , Germany
Urologie Schlosscarree
Braunschweig, , Germany
Urologische Praxis Dr. Krieger
Chemnitz, , Germany
Zeisigwaldkliniken Bethanien
Chemnitz, , Germany
St. Georg Klinikum Eisenach GmbH
Eisenach, , Germany
St. Franziskus-Hospital; Malteser Krankenhaus; Medizinische Klinik I
Flensburg, , Germany
Klinikum Frankfurt Höchst GmbH; Klinik Innere Medizin 3 - Hämatologie, Onkologie, Palliativmedizin
Frankfurt am Main, , Germany
Dres.Jochen Wilke und Harald Wagner
Fürth, , Germany
Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
Halle, , Germany
Urologische Praxis Michael Steinacker
Halle, , Germany
Asklepios Klinik Altona, Abteilung für Urologie
Hamburg, , Germany
Onkologische Praxis in Heidenheim
Heidenheim, , Germany
St. Bernward-Krankenhaus
Hildesheim, , Germany
Onkologische Praxis Landshut
Landshut, , Germany
Gemeinschaftspraxis; Onkologisches Zentrum Lebach; Caritas Krankenhaus Lebach
Lebach, , Germany
ÜBAG MVZ Mitte / MVZ Delitzsch GmbH, Standort Leipzig
Leipzig, , Germany
Sankt Elisabeth Krankenhaus; Urlogische Abt.
Leipzig, , Germany
Drk Krankenhaus Luckenwalde
Luckenwalde, , Germany
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Urologie
Lübeck, , Germany
Urologikum Lübeck
Lübeck, , Germany
Urologischen Praxis in Lüneburg
Lüneburg, , Germany
Medizinische Fakultät Mannheim, Universitätsklinikum Mannheim, Klinik für Urologie
Mannheim, , Germany
Praxis Markkleeberg
Markkleeberg, , Germany
Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Hämatologie, Onkologie und Pallia.
Minden, , Germany
Städt.Kliniken München GmbH Klinikum Bogenhausen
München, , Germany
Praxis Dr. Uhlig, Naunhof
Naunhof, , Germany
Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie/Onkologie
Paderborn, , Germany
Praxis für Hämatologie & Onkologie
Saarbrücken, , Germany
MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
Stade, , Germany
Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie
Trier, , Germany
Urologische Praxis
Wedel, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie Westerstede Aurich Rhauder
Westerstede, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML39704
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.